Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | C1S | P09871 | 1/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067224 | 0.84 | C5AR1 (0.43) | SMN1; SMN2C5AR1 | |
| SCHEMBL31095476 | 0.72 | GRM5 (0.41) | SMN1; SMN2C5AR1 | |
| SCHEMBL10408119 | 0.68 | ALOX5 (0.49) | MAOBC1SBPTFHTTSMN1; SMN2 | |
| SCHEMBL27866034 | 0.67 | EED (0.54) | SMN1; SMN2 | |
| SCHEMBL31067173 | 0.67 | ADRA1A (0.41) | HTT | |
| SCHEMBL22715552 | 0.67 | P2RX3 (0.37) | — | |
| SCHEMBL31067171 | 0.67 | ADRA1A (0.41) | HTT | |
| SCHEMBL31067120 | 0.67 | ADRA1A (0.41) | HTT | |
| SCHEMBL29439864 | 0.67 | P2RX3 (0.37) | — | |
| SCHEMBL20699709 | 0.66 | BPTF (0.54) | C1SBPTFHTTSMN1; SMN2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024180499-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | RECQL, NRAS, RAB1A | MAOB 1211/4885C1S 3426/4885BPTF 3122/4885 |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | RECQL, NRAS, RAB1A | MAOB 1211/4885C1S 3426/4885BPTF 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.